CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2020-01-22
Target enrollment:
Participant gender:
Summary
This phase II trial studies the best dose and how well liposomal cytarabine-daunorubicin
CPX-351 (CPX-351) works in treating patients with newly diagnosed acute myeloid leukemia and
who are at risk for not responding well to treatment. Liposomal cytarabine-daunorubicin
CPX-351 combines two chemotherapy drugs that are known to help each other work better, and
may work to stop the growth of cancer cells by blocking the cells from dividing.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Celator Pharmaceuticals National Cancer Institute (NCI)